Business Wire

IFF expands LMR Naturals site in Grasse, advancing naturals innovation leadership

8.9.2025 11:00:00 CEST | Business Wire | Press Release

Share

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, today inaugurated its expanded LMR Naturals site in Grasse following a €10 million investment. The expansion increases the facility’s footprint by 75 percent to 4,687 square meters and includes a state-of-the-art pilot hall designed to accelerate the development of new natural ingredients. The upgraded site also counts on a newly completed experimental field nearby that will provide direct access to plant materials, enabling deeper exploration of botanical potential and fast-tracking ingredient innovation. The expansion brings together more than 30 research and development experts under one roof, enhancing IFF’s ability to meet rising global demand for traceable, sustainable and high-quality naturals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908487443/en/

Credit: IFF

“LMR Naturals is a strategic asset in IFF’s portfolio, and this expansion underscores our commitment to shaping the future of natural ingredients,” said Erik Fyrwald, IFF CEO. “By deepening our roots in Grasse — the global center of excellence for natural ingredients — we’re scaling innovation that empowers perfumers and flavorists worldwide to deliver high-performing, exceptional and sustainable signatures consumers trust.”

LMR Naturals is a trademarked capability within IFF, originally founded in 1983 by Monique Remy and acquired by IFF in 2000 to enhance IFF’s ability to provide perfumers with high-quality, innovative and, sustainably sourced and produced natural ingredients at competitive cost. Today, perfumers around the world leverage the deep expertise of LMR scientists to create the signature of unforgettable fragrances for customers and across applications such as fine perfumery, cosmetics, home care, fabric care and beauty care. LMR Naturals also provides ingredients for taste applications.

“LMR’s ability to fuse tradition with cutting-edge innovation is unmatched,” said Sabrya Meflah, president of IFF’s fine fragrance segment. “This expansion is more than bricks and mortar—it’s a launchpad for the next generation of naturals that will shape the future of fine perfumery, with applications across all IFF businesses. Our footprint in Grasse now enables a seamless transition from seed to bottle, with our Atelier du Parfumeur just steps away.”

“With a newly expanded site now fully operational, we intend to launch four to six new products each year, with sustainability at the heart of our approach — reflected in our dual certifications, For Life and Zero Waste to Landfill, and a waste valorization rate of at least 98 percent,” said Bertrand de Preville, general manager of LMR Naturals.

LMR Naturals introduced 23 new ingredients since 2020 and earned notable accolades, including seven awards from CosmetiqueMag and recognition from the Organic Monitor Sustainable Beauty Awards. Meanwhile, the LMR Naturals team remains committed to its founding vision: revealing the purity of natural ingredients while respecting the environment and sourcing partners. LMR currently processes 85,000 tons of biomass annually, produces 2,000 tons of extracts and offers more than 850 ingredients across 130 botanical families.

With this expansion, IFF reaffirms its strategic investment in the Grasse region, which now includes more than 230 employees and positions it as a global hub for natural ingredient innovation and excellence.

Visit LMR Naturals at https://lmrnaturals.iff.com, LinkedIn, and Instagram.

Cautionary Statement under the Private Securities Litigation Reform Act of 1995

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “plan”, “expect,” “anticipate,” “intend,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of the expansion, its operations or future product launches. There are many risks and uncertainties inherent in our business that could cause actual results and events to differ materially from those in the forward-looking statements. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook.

© 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250908487443/en/

Contacts

Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com

Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye